-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $20

Benzinga·12/22/2025 13:01:30
語音播報
Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $19 to $20.